Schizophrenia is a devastating mental illness characterized by symptoms eg hallucinations, disorganized thinking, loss of goal-directed behaviors and deterioration in social role functioning.
Positive or psychotic symptoms are delusions, hallucinations, and distorted perceptions.
Negative symptoms include flat or blunted emotions, lack of motivation or energy, lack of pleasure or interest in things, and limited speech.
Disorganized symptoms are confused thinking, disorganized speech and behavior.
Cognitive symptoms include impairment in attention verbal fluency memory, and executive functioning.
New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine, appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.
Continuous primary care follow-up during the transition from adolescence to young adulthood could reduce the risk of mental illness-related hospitalizations post-transition in individuals with severe mental illness, according to a Canadian study.
Relapse in schizophrenia appears to contribute to increased treatment resistance, with a recent study showing that response to antipsychotic medication is reduced or delayed in patients who relapse after effective treatment of the first episode.
Children born to parents with schizophrenia are at increased risk of developing a variety of neurological disorders, as well as visual and hearing disorders, at an early age, a study has found. The same is true for those born to parents with a major depression.
Antipsychotic drug treatment appears to be less effective in patients with higher polygenic risk score (PRS) for schizophrenia, suggests a study. PRS burden appears to be useful as a prognostic biomarker.
First-recorded diagnoses of psychiatric disorders are associated with increases in risk of subsequent self-harm that vary by diagnostic categories across gender and age groups, with the highest risk observed in patients with substance misuse or dependence, a 10-year case-control study in Hong Kong has shown.